DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Provayblue is a drug marketed by Provepharm Sas and is included in one NDA.
The generic ingredient in PROVAYBLUE is methylene blue. There are twenty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the methylene blue profile page.
Generic Entry Opportunity Date for PROVAYBLUE
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for PROVAYBLUE
Identify potential brand extensions & 505(b)(2) entrants
|Provepharm Life Solutions||Phase 2|
|Carilion Clinic||Phase 2|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Provepharm Sas||PROVAYBLUE||methylene blue||SOLUTION;INTRAVENOUS||204630-002||Jul 18, 2019||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|Provepharm Sas||PROVAYBLUE||methylene blue||SOLUTION;INTRAVENOUS||204630-001||Apr 8, 2016||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|